Low Incidence of Adverse Events for A-Fib Catheter Ablation

Share this content:
Low Incidence of Adverse Events for A-Fib Catheter Ablation
Low Incidence of Adverse Events for A-Fib Catheter Ablation

FRIDAY, Sept. 1, 2017 (HealthDay News) -- The incidence of adverse events (AEs) is low for patients undergoing catheter ablation (CA) for atrial fibrillation (AF), according to a study published online Aug. 30 in JACC: Clinical Electrophysiology.

Michelle Samuel, M.P.H., from the McGill University Health Center Research Institute in Montreal, and colleagues examined the safety and incidence of peri-procedural AEs among patients who underwent CA for AF between 1999 and 2014 in Canada. The authors assessed the incidence and predictors of AEs within 30 days of CA.

The researchers found that 3.5 percent of the 6,388 patients who had a CA developed major AEs within 30 days of index CA; the most frequent was hemorrhage/hematoma (1.4 percent), followed by pericardial effusion requiring drainage (PERD; 1.0 percent) and cerebrovascular accident (CVA; 0.6 percent). The likelihood of PERD was higher post-discharge than during the index CA (P < 0.05). In patients with recent versus remote CA, CVA decreased by more than 50 percent (P < 0.05). The incidence of PERD and hemorrhage/hematoma was greater at first repeat CA versus index CA (P < 0.05 for both).

"CA is a relatively safe procedure with low incidence of major AEs," the authors write. "The incidence of procedure-related CVA appeared to decline significantly over time."

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »